The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 5, 2014, Pages 457-469

  Mourouzis, Iordanis ^a   Mantzouratou, Polixeni ^a   Galanopoulos, Georgios ^a   Kostakou, Erietta ^a   Dhalla, Arvinder K ^b   Belardinelli, Luiz ^b   Pantos, Constantinos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b GILEAD SCIENCES   (United States)

Author keywords

Diabetes; Insulin; Intracellular kinase signaling; Myocardial infarction; Ranolazine

Indexed keywords

GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE B; RANOLAZINE; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; GLUCOSE BLOOD LEVEL; MITOGEN ACTIVATED PROTEIN KINASE P38; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; INSULIN BLOOD LEVEL; ISOLATED HEART; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WISTAR RAT; ANIMAL; BLOOD; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HEART FUNCTION TEST; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; TREATMENT OUTCOME;

ACETANILIDES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HEART FUNCTION TESTS; INSULIN; MALE; MYOCARDIAL INFARCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; RANOLAZINE; RATS; RATS, WISTAR; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84928107038     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414524481     Document Type: Article

References (50)

1. Chiha M, Njeim M, Chedrawy EG. Diabetes and coronary heart disease: A risk factor for the global epidemic. Int J Hypertens. 2012;2012:697240.
2. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298(7): 765-775.
3. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20(3):736-744.
4. Carrabba N, Valenti R, Parodi G, Santoro GM, Antoniucci D. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. Circulation. 2004;110(14):1974-1979.
5. Aldakkak M, Camara AK, Heisner JS, Yang M, Stowe DF. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011;64(4):381-392.
6. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006;41(6):1031-1038.
7. Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between nonsustained ventricular tachycardia after non-STelevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromethrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122(5):455-462.
8. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010;33(6): 1163-1168.
9. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in theMERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032-2039.
10. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina. results from the TERISA randomized clinical trial. J Am Coll Cardiol. 2013;61(20):2038-2045.
11. Ishitani T, Kishida S, Hyodo-Miura J, et al. The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23(1):131-139.
12. Yasuoka C, Ihara Y, Ikeda S, Miyahara Y, Kondo T, Kohno S. Antiapoptotic activity of Akt is down-regulated by Ca2+ in myocardiac H9c2 cells. Evidence of Ca(2+)-dependent regulation of protein phosphatase 2Ac. J Biol Chem. 2004;279(49): 51182-51192.
13. Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res. 2012;111(6): 800-814.
14. Cittadini A, Monti MG, Iaccarino G, et al. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther. 2006;13(1):8-19.
15. Kim YK, Kim SJ, Yatani A, et al.Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed. Akt J Biol Chem. 2003;278(48):47622-47628.
16. Kalofoutis C, Mourouzis I, Galanopoulos G, et al. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem. 2010;345(1-2): 161-169.
17. Pantos C, Mourouzis I, Markakis K, et al. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg. 2007;32(2):333-339.
18. Pantos C, Mourouzis I, Markak is K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008; 103(4):308-318.
19. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-491.
20. Pantos C, Mourouzis I, Galanopoulos G, et al. Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: The potential role of tissue hypothyroidism. Horm Metab Res. 2010;42(10):718-724.
21. Pantos C, Mourouzis I, Saranteas T, et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: A new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009; 104(1):69-77.
22. Mourouzis I, Giagourta I, Galanopoulos G, et al. Thyroid hormone improves the mechanical performance of the postinfarcted diabetic myocardium: A response associated with upregulation of Akt/mTOR and AMPK activation. Metabolism. 2013;62(10):1387-1393.
23. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213-3223.
24. Hall KE, McDonald MW, Grise KN, Campos OA, Noble EG, Melling CW. The role of resistance and aerobic exercise training on insulin sensitivity measures in STZ-induced type 1 diabetic rodents. Metabolism. 2013;62(10):1485-1494.
25. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: Mechanisms: part 1 of 2. Circulation. 2013;128(4): 388-400.
26. Mourouzis I, Kostakou E, Galanopoulos G, Mantzouratou P, Pantos C. Inhibition of thyroid hormone receptor alpha1 impairs post-ischemic cardiac performance after myocardial infarction in mice. Mol Cell Biochem. 2013;379(1-2):97-105.
27. Luo M, Guan X, Luczak ED, et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013;123(3):2333-2374.
28. Ma G, Al-Shabrawey M, Johnson JA, et al. Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):415-427.
29. Pantos C, Mourouzis I, Cokkinos DV. Protection of the abnormal heart. Heart Fail Rev. 2007;12(3-4):319-330.
30. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: The importance of Akt phosphorylation. Diabetes. 2005;54(8):2360-2364.
31. Xu G, Takashi E, Kudo M, Ishiwata T, Naito Z. Contradictory effects of short- And long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway. Exp Mol Pathol. 2004;76(1):57-65.
32. Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol. 2011;50(6):940-950.
33. Molkentin JD. Dichotomy of Ca2+ in the heart: contraction versus intracellular signaling. J Clin Invest. 2006;116(3):623-626.
34. Latronico MV, Costinean S, Lavitrano ML, Peschle C, Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci. 2004;1015:250-260.
35. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation. 2007;116(12):1413-1423.
36. Takeda K, Matsuzawa A, Nishitoh H, et al. Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Rep. 2004; 5(2):161-166.
37. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23(10):1515-1527.
38. Fredersdorf S, Thumann C, Zimmermann WH, et al. Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol. 2012;11:57.
39. Ning Y, Zhen W, Fu Z, et al. Ranolazine increases beta-cell survival and improves glucose homeostasis in low-dose streptozotocininduced diabetes in mice. J Pharmacol Exp Ther. 2011;337(1): 50-58.
40. Ding WG, Kitasato H. Suppressing Na+ influx induces an increase in intracellular ATP concentration in mouse pancreatic beta-cells. Jpn J Physiol. 1997;47(3):299-306.
41. Iezzi M, Kouri G, Fukuda M, Wollheim CB. Synaptotagmin V and IX isoforms control Ca2+-dependent insulin exocytosis. J Cell Sci. 2004;117(pt 15):3119-3127.
42. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res. 2012;110(12): 1646-1660.
43. Oliveira SM, Zhang YH, Solis RS, et al. AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res. 2012; 110(9):1192-1201.
44. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104(3):403-411.
45. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res. 2007;100(4): 474-488.
46. Ji L, Zhang X, Liu W, et al. AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS One. 2013; 8(7):e69910.
47. Howell NJ, Ashrafian H, Drury NE, et al. Glucose-insulinpotassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation. 2011; 123(2):170-177.
48. Lymvaios I, Mourouzis I, Cokkinos DV, et al. Thyroid hormone and recovery of cardiac function in patients with acutemyocardial infarction: A strong association? Eur J Endocrinol. 2011;165(1):107-114.
49. Springeling T, Kirschbaum SW, Rossi A, et al. Late cardiac remodeling after primary percutaneous coronary intervention. Circ J. 2012;77(1):81-88.
50. Yin M, Westenbrink B, Meissner M, van Gilst WH, de Boer RA. Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. Int J Cardiol. 2013;169(6):385-393.